



(11) **EP 1 765 832 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
25.09.2013 Bulletin 2013/39

(45) Date of publication and mention
of the grant of the patent:
14.08.2013 Bulletin 2013/33

(21) Application number: **05752679.0**

(22) Date of filing: **13.06.2005**

(51) Int Cl.:
C07D 498/08 ^(2006.01) **A61K 31/438** ^(2006.01)
A61P 9/06 ^(2006.01)

(86) International application number:
PCT/SE2005/000891

(87) International publication number:
WO 2005/123748 (29.12.2005 Gazette 2005/52)

(54) **NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS**

NEUE OXABISPIDINVERBINDUNGEN UND DEREN VERWENDUNG BEI DER BEHANDLUNG VON HERZRHYTHMUSSTÖRUNGEN

NOUVEAUX COMPOSES OXABISPIDINE ET LEUR UTILISATION DANS LE TRAITEMENT DES ARYTHMIES CARDIAQUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR LV MK YU

(30) Priority: **15.06.2004 SE 0401539**

(43) Date of publication of application:
28.03.2007 Bulletin 2007/13

(73) Proprietor: **Animeda AB**
436 55 Hovås (SE)

(72) Inventors:
• **BJÖRE, Annika**
S-431 83 Mölndal (SE)
• **BONN, Peter**
S-431 83 Mölndal (SE)

- **GRAN, Ulrik**
S-431 83 Mölndal (SE)
- **KAJANUS, Johan**
S-431 83 Mölndal (SE)
- **OLSSON, Christina**
S-431 83 Mölndal (SE)
- **PONTEN, Fritiof**
S-431 83 Mölndal (SE)

(74) Representative: **Storm, Jan Peter et al**
AstraZeneca
Intellectual Property
Alderley Park
Macclesfield
Cheshire SK10 4TG (GB)

(56) References cited:
WO-A1-02/28863 WO-A2-01/28992

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).